March 29 Reuters Gerresheimer CEO Dietmar Siemssen said he expects about 4 of the company39;s revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors.

The German company reported in February that it expects to grow an average of 10 per year. Nearly half of that will come from its association with drugs in the GLP1 class, the CEO told Reuters. Novo Nordisk39;s popular obesity drug Wegovy and Eli Lilly39;s in demand Zepbound are GLP1 drugs.

Siemssen said he expects sales related to GLP1 medicines to surpass 100 million euros this year and to reach at least 350 million euros 379 million within the next three years, based on actual contracts and orders.

We are just at the beginning of the ramp up towards the total market for these drugs, and the biggest growth you will see from 2025 to 2027, he said.

Two analysts contacted by Reuters said they expect Wegovy on average to bring in sales of about 8.6 billion this year and 12.86 billion in 2025. They forecast sales of Zepbound to be around 4 billion this year and 10.8 billion next year.

Originally developed for type 2 diabetes, GLP1s also reduce food cravings and cause the stomach to empty more slowly.

Analysts see the weightloss drug market reaching at least 100 billion by the end of the decade, as consumers flock to Wegovy and Zepbound, which have been shown to reduce weight by as much as 20, and other medicines in development….